FTC Says "Orange Book" Abuse Blocks Drug Competition
The Federal Trade Commission urged a Delaware federal court to remove a patent for narcolepsy drug distribution from federal regulators' list of approved drugs and the patents covering them, arguing the patent was improperly included and...To view the full article, register now.
Already a subscriber? Click here to view full article